Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Isis, JNJ diabetes deal

Johnson & Johnson and ISIS partnered to discover, develop and commercialize antisense treatments for Type II diabetes and other diseases. ISIS

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE